VC-backed Profound Medical to commence trading on TSX Venture Exchange

Profound Medical Inc, a Toronto-based medical device company focused on treatments for prostate cancer, has completed its previously announced going-public transaction via a reverse take-over of Mira IV Acquisition Corp. It is expected to commence trading on the TSX Venture Exchange under the ticker symbol "PRN" on June 8, 2015. The company also wrapped up its previously disclosed private placement, securing gross proceeds of about $24 million. Canadian venture capital firms BDC Capital and Genesys Capital, which committed to the deal, currently hold about 24.9 percent and 23.1 percent, respectively, of Profound Medical's total issued and outstanding shares.

CanadaNorth AmericaBriefs